ICIs are monoclonal antibodies that block inhibitory regulatory proteins. Their use leads to T-cell activation, engaging the immune system to treat the malignancy.2 ICI toxicities, known as IRAEs, range from mild skin rash to fatal myocarditis.3 There are no clinical trials to guide IRAE management, and treatment is based on management of autoimmune diseases outside the ICI setting.
Reid PD, Cifu AS, Bass AR. Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy. JAMA. 2021;325(5):482–483. doi:10.1001/jama.2020.17308
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: